Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Drug Profile

Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Alternative Names: BioMed rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft; ORG 28077; rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Latest Information Update: 28 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomedizinische Forschungsgesellschaft
  • Class Bacterial vaccines; Protein-vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 01 May 2016 Biomedizinische Forschungsgesellschaft completes a phase I trial for Bacterial infections (Prevention) in Austria (NCT02971670)
  • 29 Mar 2016 Phase-II clinical trials in Bacterial infections (Prevention) in Austria (IM)
  • 22 Jul 2015 Biomedizinische Forschungsgesellschaft completes a phase I trial in Staphylococcal infections in Austria (NCT02340338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top